Efficacy and safety of prostatic artery embolization for benign prostatic hyperplasia: a systematic review and meta-analysis of randomized controlled trials

被引:29
|
作者
Xiang, Peng [1 ,2 ,3 ]
Guan, Di [1 ]
Du, Zhen [1 ]
Hao, Yongxiu [4 ]
Yan, Wei [1 ]
Wang, Yonghui [1 ]
Liu, Yutong [1 ]
Liu, Dan [1 ]
Ping, Hao [1 ,2 ,3 ]
机构
[1] Capital Med Univ, Beijing Tongren Hosp, Dept Urol, 1 Dongjiaomingxiang St, Beijing 100730, Peoples R China
[2] Beihang Univ, Beijing Adv Innovat Ctr Big Data Based Precis Med, Beijing 100730, Peoples R China
[3] Capital Med Univ, Beijing Tongren Hosp, Beijing 100730, Peoples R China
[4] Peking Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Beijing 100191, Peoples R China
基金
中国国家自然科学基金;
关键词
Benign prostatic hyperplasia; Embolization; therapeutic; Lower urinary tract symptoms; Systematic review; Meta-analysis;
D O I
10.1007/s00330-020-07663-2
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objective To investigate the efficacy and safety of prostatic artery embolization (PAE) vs. transurethral resection of the prostate (TURP) in patients affected by benign prostatic hyperplasia (BPH). We also reviewed mean changes from baseline in PAE at selected follow-up points. Methods PubMed, Web of Science, and Embase were searched up to May 1, 2020. Randomized controlled trials on PAE were collected according to specific inclusion and exclusion criteria. Meta-analyses were performed using RevMan 5.3, STATA 14, and GraphPad Prism 8. Pooled patient-reported scores and functional outcomes were calculated by using a fixed or random-effect model. Results Eleven articles met our selection criteria and ten independent patient series were included in the final analysis. Pooled estimates suggested no significant difference between TURP and PAE for patient-reported outcomes including International Prostate Symptom Score (2.32 (- 0.44 to 5.09)) and quality of life (0.18 (- 0.41 to 0.77)) at 12 months. PAE was less effective regarding improvements in most functional outcomes such as maximum flow rate, prostate volume, and prostate-specific antigen. Moreover, PAE may be associated with relatively fewer complications, lower cost, and shorter hospitalization. After the PAE procedure, the overall weighted mean differences for all outcomes except sexual health scores were significantly improved from baseline during follow-up to 24 months. Conclusion PAE is non-inferior to TURP with regard to improving patient-reported outcomes, though most functional parameters undergo more changes after TURP than after PAE. Moreover, PAE can significantly continue to relieve symptoms for 24 months without causing serious complications. Key Points PAE is as effective as TURP in improving subjective symptom scores, with fewer complications and shorter hospitalization times. PAE is inferior to TURP in the improvement of most functional outcomes. Improvements due to PAE are durable during follow-up to 24 months.
引用
收藏
页码:4929 / 4946
页数:18
相关论文
共 50 条
  • [31] Two year efficacy of prostatic urethral lift for benign prostatic hyperplasia: A systematic review and meta-analysis
    Almidani, O.
    Al Ameeri, A.
    Almallah, Z.
    EUROPEAN UROLOGY, 2022, 81 : S1059 - S1061
  • [32] Efficacy and safety of enucleation vs. resection of prostate for treatment of benign prostatic hyperplasia: a meta-analysis of randomized controlled trials
    Yucong Zhang
    Penghui Yuan
    Delin Ma
    Xintao Gao
    Chao Wei
    Zhuo Liu
    Rui Li
    Shaogang Wang
    Jihong Liu
    Xiaming Liu
    Prostate Cancer and Prostatic Diseases, 2019, 22 : 493 - 508
  • [33] Efficacy and safety of enucleation vs. resection of prostate for treatment of benign prostatic hyperplasia: a meta-analysis of randomized controlled trials
    Zhang, Yucong
    Yuan, Penghui
    Ma, Delin
    Gao, Xintao
    Wei, Chao
    Liu, Zhuo
    Li, Rui
    Wang, Shaogang
    Liu, Jihong
    Liu, Xiaming
    PROSTATE CANCER AND PROSTATIC DISEASES, 2019, 22 (04) : 493 - 508
  • [34] Radiation dose of prostatic artery embolization for benign prostatic hyperplasia: A protocol for systematic review
    Liu, Jinglei
    Zhang, Kai
    Wu, Xiaolong
    Cui, Bao
    Liang, Zhihui
    MEDICINE, 2022, 101 (46) : E31595
  • [36] DUTASTERIDE FOR BENIGN PROSTATIC HYPERPLASIA: A SYSTEMATIC REVIEW AND META-ANALYSIS
    Park, T.
    Shamliyan, T. A.
    VALUE IN HEALTH, 2011, 14 (03) : A74 - A74
  • [37] Acupuncture for benign prostatic hyperplasia: A systematic review and meta-analysis
    Zhang, Wei
    Ma, Liyan
    Bauer, Brent A.
    Liu, Zhishun
    Lu, Yao
    PLOS ONE, 2017, 12 (04):
  • [38] Meta-analysis of Randomized trials of terazosin in the treatment of benign prostatic hyperplasia
    Boyle, P
    Robertson, C
    Manski, R
    Padley, RJ
    Roehrborn, CG
    JOURNAL OF UROLOGY, 2002, 168 (01): : 403 - 403
  • [39] Efficacy and safety of dutasteride for the treatment of symptomatic benign prostatic hyperplasia (BPH): a systematic review and meta-analysis
    Luca Cindolo
    Mario Alvarez-Maestro
    Roberto Castellucci
    Luigi Schips
    World Journal of Urology, 2015, 33 : 441 - 442
  • [40] Efficacy and safety of dutasteride for the treatment of symptomatic benign prostatic hyperplasia (BPH): a systematic review and meta-analysis
    Taehwan Park
    Jae-Young Choi
    World Journal of Urology, 2014, 32 : 1093 - 1105